ClinicalTrials.gg
Not yet recruitingNCT07857928ALB-SARDSUpdated Nov 17, 2026

Effect of Albumin Therapy in Mechanically Ventilated Patients With Sepsis-Associated ARDS

An observational study in Acute Respiratory Distress Syndrome, Sepsis and Hypoalbuminemia, sponsored by The Second Affiliated Hospital of Hainan Medical University. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by The Second Affiliated Hospital of Hainan Medical University · Observational

How we know

Updated Nov 17, 2026Start date movedNewly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
260
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 146 studies in Respiratory Distress Syndrome with a site in China — 54 open to participants now, 55 under way, 6 of them phase 3. Respiratory Distress Syndrome · China.

Planned enrollment
28th of 65
260 · median 139
Started
2026
with 13 others
Observational
65 of 146
22 open now
Primary completion
2027-10
later than 41 of 54 live
Registered
145th of 146
by date

Among the 146 studies in Respiratory Distress Syndrome with a site in China, this one is the 28th largest by planned enrollment of the 65 observational ones that give a count, is one of 14 that started in 2026, is one of 65 observational ones, reaches primary completion later than 41 of the 54 other live ones, and was the 145th registered.

Respiratory Distress Syndrome

1,389 studies on the registry are indexed under Respiratory Distress Syndrome; 281 are open to participants now.

Browse Respiratory Distress Syndrome studies →

Open to participants now

54 of the 146 studies in Respiratory Distress Syndrome with a site in China are open now. Recruiting first, the newest first:

49 more — sign in →

All 54 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 196 Respiratory Distress Syndrome studies recruiting now, 116 (59%) set no upper age limit and 50 (26%) stop at 75 or younger; 52 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 146 studies in Respiratory Distress Syndrome with a site in China, or all of them as a file.
02

Study summary

Sepsis-associated acute respiratory distress syndrome (ARDS) is a severe condition where severe infection causes fluid accumulation in the lungs, often requiring invasive mechanical ventilation. Patients with low blood albumin levels are particularly vulnerable to this fluid leakage, leading to prolonged dependence on a ventilator.

This observational study evaluates the association between a targeted human albumin treatment strategy combined with clinically guided fluid removal, and clinical outcomes in adults with sepsis-associated ARDS and low blood albumin levels (≤ 30 g/L).

Conducted at a single hospital, this study compares two groups. The prospective group consists of patients receiving current usual clinical care, where albumin administration and fluid management are determined by the treating clinical team. Their outcomes will be compared to a historical control group of similar patients who received standard care before this targeted albumin management strategy was routinely implemented.

The primary objective is to evaluate whether this targeted albumin strategy is associated with an increase in Ventilator-Free Days at day 28 (VFD-28). VFD-28 reflects both patient survival and successful liberation from the ventilator. The study will also observe secondary outcomes including oxygenation improvement, fluid balance, organ function, mortality, and safety events (e.g., fluid overload or allergic reactions). As an observational study, researchers do not assign treatments; all interventions are based on real-world clinical judgment.

Read the detailed description

Background and Rationale Hypoalbuminemia is common in patients with sepsis-associated ARDS and alters colloid osmotic pressure, exacerbating pulmonary edema and prolonging mechanical ventilation. While human albumin administration during the de-resuscitation phase may support intravascular volume and facilitate fluid removal (via diuretics or CRRT), real-world evidence evaluating a structured, targeted albumin strategy specifically in this vulnerable subpopulation remains limited.

Study Design and Cohorts This is a single-center, prospective observational study with a historical control cohort. The study employs a before-and-after design to evaluate real-world clinical outcomes.

Historical Control Cohort: Eligible patients identified retrospectively who received usual clinical care (primarily crystalloid-based fluid management) prior to the routine implementation of the targeted albumin strategy. Any occasional albumin use in this cohort will be documented and adjusted for in statistical analyses.

Prospective Observational Cohort: Eligible patients receiving current standard of care, which includes human albumin administration (aiming for serum albumin ≥ 30 g/L) and fluid de-resuscitation. Treatment decisions, including albumin dose, frequency, and fluid targets, remain entirely under the discretion of the treating clinical team.

Time Origin (Time Zero, T0) Definition To strictly prevent immortal time bias, the study time origin (T0) is defined as the exact timestamp when a patient simultaneously fulfills all required eligibility conditions: (1) Sepsis-3 criteria met, (2) ARDS criteria met, (3) invasive mechanical ventilation active, and (4) confirmed serum albumin ≤ 30 g/L. All baseline covariates, propensity score matching variables, and outcome observation windows strictly anchor to T0. If mechanical ventilation begins before T0, the actual ventilation start time is retained for the ventilation history but outcome computation (e.g., VFD-28) strictly starts at T0.

Exposure Definition (Observational Context) The primary exposure is management with a targeted human albumin strategy combined with fluid de-resuscitation. As an observational study, the protocol does not mandate therapy. Instead, it observes and records treatments delivered in routine clinical care. Data on albumin concentration, cumulative dose, fluid intake/output, diuretic use, and CRRT net ultrafiltration are prospectively collected.

Outcome Assessment and Statistical Analysis The primary outcome is Ventilator-Free Days at day 28 (VFD-28), calculated from T0. Patients who die within 28 days are assigned zero VFDs.

To mitigate confounding by indication and calendar time bias, a 1:1 Propensity Score Matching (PSM) will be utilized. Covariates (e.g., age, APACHE II, baseline SOFA, PaO2/FiO2, lactate, and cumulative fluid balance) are strictly restricted to pre-T0 values to avoid overadjustment by post-treatment mediators.

The primary outcome (VFD-28) will be analyzed evaluating the absolute difference between matched groups. As a key secondary analysis, a Fine-Gray competing-risk model will be used to evaluate the cumulative incidence of successful liberation from ventilation, treating death as a competing event. Repeated measures (e.g., albumin levels, oxygenation) will be evaluated using generalized estimating equations (GEE) or linear mixed-effects models (LMM).

03

Conditions studied

  • Acute Respiratory Distress Syndrome
  • Sepsis
  • Hypoalbuminemia

Keywords

  • Human Serum Albumin
  • Mechanical Ventilation
  • Fluid Management
  • De-resuscitation
  • Ventilator-Free Days
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population comprises critically ill adult patients admitted to the intensive care units (ICUs) at the Second Affiliated Hospital of Hainan Medical University. Eligible participants are those diagnosed with sepsis-associated acute respiratory distress syndrome (ARDS) who require invasive mechanical ventilation and have confirmed hypoalbuminemia (serum albumin ≤ 30 g/L). The prospective cohort is identified consecutively from active ICU admissions, while the historical control cohort is identified retrospectively from electronic medical records of patients admitted prior to the routine implementation of the targeted albumin protocol.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18 years or older.
  • Clinical diagnosis conforming to the Sepsis-3 consensus criteria.
  • Diagnosis of acute respiratory distress syndrome (ARDS) fulfilling the European Society of Intensive Care Medicine (ESICM) criteria (mild, moderate, or severe).
  • Receiving invasive mechanical ventilation, with an intubation duration ≤ 48 hours at study enrollment.
  • First admission to the intensive care unit (ICU) ≤ 24 hours prior to enrollment.
  • Baseline serum albumin concentration ≤ 30 g/L measured at hospital or ICU admission.
  • Anticipated ICU stay of > 48 hours.

Exclusion criteria

Exclusion Criteria:

  • Female patients who are pregnant or lactating.
  • Severe burn injury or currently receiving extracorporeal membrane oxygenation (ECMO) support.
  • Perioperative period of liver transplantation or decompensated liver cirrhosis ( class C).
  • End-stage or an estimated clinical \< 3 months.
  • Signed Do-Not-Resuscitate (DNR) order, agreement to withhold/withdraw active life-sustaining therapy, or moribund state expected to result in death within 24 hours.
  • Known history of severe or anaphylactic shock to human serum albumin preparations.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
260 participants (estimated)
Patient registry
No

Groups and cohorts

  • Prospective Observational Cohort

    Patients enrolled prospectively receiving current usual clinical care, which includes a targeted human albumin treatment strategy (aiming to maintain serum albumin ≥ 30 g/L) combined with protocolized fluid de-resuscitation. Treatment decisions remain entirely under the discretion of the treating clinical team.

  • Historical Control Cohort

    Patients identified retrospectively from electronic medical records who received usual clinical care (primarily crystalloid-based fluid management without a targeted albumin protocol) prior to the routine implementation of the targeted albumin strategy.

06

What researchers measure

Primary outcomes

  1. Ventilator-Free Days at Day 28 (VFD-28)

    VFD-28 is defined as the number of days from Time Zero (T0) to day 28 that a patient is alive and successfully liberated from invasive mechanical ventilation (defined as being free from the ventilator for at least 48 consecutive hours). Patients who die within the 28-day observation period are assigned zero VFDs, regardless of their ventilation status prior to death.

    Time frame: Up to 28 days from Time Zero (T0)

  2. Cumulative Incidence of Successful Liberation from Ventilation

    Analyzed using a competing-risk model (treating death as a competing event) to evaluate the probability of successful weaning from invasive mechanical ventilation.

    Time frame: Up to 28 days from Time Zero (T0)

Secondary outcomes

  1. Cumulative Fluid Balance

    The daily net fluid balance evaluated to reflect the de-resuscitation trajectory. It is calculated by subtracting total fluid output (including net ultrafiltration from CRRT, if applicable) from total fluid intake.

    Time frame: From Day 1 to Day 7

  2. Change in Oxygenation Index (PaO2/FiO2 Ratio)

    The daily worst PaO2/FiO2 ratio measured to evaluate the trajectory of lung function and pulmonary edema resolution.

    Time frame: From Day 1 to Day 7

  3. 28-Day All-Cause Mortality

    The proportion of patients who die from any cause within the 28-day observation period.

    Time frame: At Day 28

07

Study locations

1 site
08

References and documents

Publications

  • National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network; Wiedemann HP, Wheeler AP, Bernard GR, Thompson BT, Hayden D, deBoisblanc B, Connors AF Jr, Hite RD, Harabin AL. Comparison of two fluid-management strategies in acute lung injury. N Engl J Med. 2006 Jun 15;354(24):2564-75. doi: 10.1056/NEJMoa062200. Epub 2006 May 21. PubMed 16714767 ↗
  • Grasselli G, Calfee CS, Camporota L, Poole D, Amato MBP, Antonelli M, Arabi YM, Baroncelli F, Beitler JR, Bellani G, Bellingan G, Blackwood B, Bos LDJ, Brochard L, Brodie D, Burns KEA, Combes A, D'Arrigo S, De Backer D, Demoule A, Einav S, Fan E, Ferguson ND, Frat JP, Gattinoni L, Guerin C, Herridge MS, Hodgson C, Hough CL, Jaber S, Juffermans NP, Karagiannidis C, Kesecioglu J, Kwizera A, Laffey JG, Mancebo J, Matthay MA, McAuley DF, Mercat A, Meyer NJ, Moss M, Munshi L, Myatra SN, Ng Gong M, Papazian L, Patel BK, Pellegrini M, Perner A, Pesenti A, Piquilloud L, Qiu H, Ranieri MV, Riviello E, Slutsky AS, Stapleton RD, Summers C, Thompson TB, Valente Barbas CS, Villar J, Ware LB, Weiss B, Zampieri FG, Azoulay E, Cecconi M; European Society of Intensive Care Medicine Taskforce on ARDS. ESICM guidelines on acute respiratory distress syndrome: definition, phenotyping and respiratory support strategies. Intensive Care Med. 2023 Jul;49(7):727-759. doi: 10.1007/s00134-023-07050-7. Epub 2023 Jun 16. PubMed 37326646 ↗
  • Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C, Machado FR, Mcintyre L, Ostermann M, Prescott HC, Schorr C, Simpson S, Wiersinga WJ, Alshamsi F, Angus DC, Arabi Y, Azevedo L, Beale R, Beilman G, Belley-Cote E, Burry L, Cecconi M, Centofanti J, Coz Yataco A, De Waele J, Dellinger RP, Doi K, Du B, Estenssoro E, Ferrer R, Gomersall C, Hodgson C, Moller MH, Iwashyna T, Jacob S, Kleinpell R, Klompas M, Koh Y, Kumar A, Kwizera A, Lobo S, Masur H, McGloughlin S, Mehta S, Mehta Y, Mer M, Nunnally M, Oczkowski S, Osborn T, Papathanassoglou E, Perner A, Puskarich M, Roberts J, Schweickert W, Seckel M, Sevransky J, Sprung CL, Welte T, Zimmerman J, Levy M. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Intensive Care Med. 2021 Nov;47(11):1181-1247. doi: 10.1007/s00134-021-06506-y. Epub 2021 Oct 2. No abstract available. PubMed 34599691 ↗
  • Sakr Y, Nierhaus A, Schumacher U, Utzolino S, Jaschinski U, Petros S, Fichtner F, Eimer C, Putensen C, Tanev I, Kreienbuhl L, Kluge S, Kousoulas L, Kuhn SO, Jarczak D, Quintel M, Bauer M; SepNet Critical Care Trials Group and Albumin Replacement Therapy in Septic Shock (ARISS) investigators. Albumin Replacement Therapy in Septic Shock: A Randomized Clinical Trial. JAMA Netw Open. 2026 Feb 2;9(2):e2559297. doi: 10.1001/jamanetworkopen.2025.59297. PubMed 41712212 ↗
  • Williams JM, Greenslade JH, Hills AZ, Ray MT. Intervention With Concentrated Albumin for Undifferentiated Sepsis in the Emergency Department (ICARUS-ED): A Pilot Randomized Controlled Trial. Ann Emerg Med. 2025 Jul;86(1):59-69. doi: 10.1016/j.annemergmed.2024.12.016. Epub 2025 Jan 23. PubMed 39846907 ↗
  • Gray AJ, Oatey K, Grahamslaw J, Irvine S, Cafferkey J, Kennel T, Norrie J, Walsh T, Lone N, Horner D, Appelboam A, Hall P, Skipworth RJE, Bell D, Rooney K, Shankar-Hari M, Corfield AR; Albumin, Balanced, and Crystalloid-Sepsis (ABC-Sepsis) Investigators. Albumin Versus Balanced Crystalloid for the Early Resuscitation of Sepsis: An Open Parallel-Group Randomized Feasibility Trial- The ABC-Sepsis Trial. Crit Care Med. 2024 Oct 1;52(10):1520-1532. doi: 10.1097/CCM.0000000000006348. Epub 2024 Jun 24. PubMed 38912884 ↗
  • Hadar L, Sood S. When knowledge is demotivating: subjective knowledge and choice overload. Psychol Sci. 2014 Sep;25(9):1739-47. doi: 10.1177/0956797614539165. Epub 2014 Jul 18. PubMed 25037963 ↗
  • Boardman K, Kelpe M, Straub D, VanFleet R. Shining through a merger. Nurs Manage. 2003 May;34(5):45-8. doi: 10.1097/00006247-200305000-00012. PubMed 12771687 ↗
  • Finfer S, Bellomo R, Boyce N, French J, Myburgh J, Norton R; SAFE Study Investigators. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med. 2004 May 27;350(22):2247-56. doi: 10.1056/NEJMoa040232. PubMed 15163774 ↗
  • Cusack RAF, Rodriguez A, Cantan B, Garduno A, Connolly E, Zilahi G, Coakley JD, Martin-Loeches I. Microcirculation properties of 20 % albumin in sepsis; a randomised controlled trial. J Crit Care. 2025 Jun;87:155039. doi: 10.1016/j.jcrc.2025.155039. Epub 2025 Feb 27. PubMed 40020556 ↗
  • Wiedermann CJ. Phases of fluid management and the roles of human albumin solution in perioperative and critically ill patients. Curr Med Res Opin. 2020 Dec;36(12):1961-1973. doi: 10.1080/03007995.2020.1840970. Epub 2020 Nov 5. PubMed 33090028 ↗
  • Aman J, van der Heijden M, van Lingen A, Girbes AR, van Nieuw Amerongen GP, van Hinsbergh VW, Groeneveld AB. Plasma protein levels are markers of pulmonary vascular permeability and degree of lung injury in critically ill patients with or at risk for acute lung injury/acute respiratory distress syndrome. Crit Care Med. 2011 Jan;39(1):89-97. doi: 10.1097/CCM.0b013e3181feb46a. PubMed 21057316 ↗
  • Fernandez-Sarmiento J, Hernandez-Sarmiento R, Salazar MP, Barrera S, Castilla V, Duque C. The association between hypoalbuminemia and microcirculation, endothelium, and glycocalyx disorders in children with sepsis. Microcirculation. 2023 Nov;30(8):e12829. doi: 10.1111/micc.12829. Epub 2023 Aug 28. PubMed 37639384 ↗
  • Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med. 2003 Apr 17;348(16):1546-54. doi: 10.1056/NEJMoa022139. PubMed 12700374 ↗
  • Bellani G, Laffey JG, Pham T, Fan E, Brochard L, Esteban A, Gattinoni L, van Haren F, Larsson A, McAuley DF, Ranieri M, Rubenfeld G, Thompson BT, Wrigge H, Slutsky AS, Pesenti A; LUNG SAFE Investigators; ESICM Trials Group. Epidemiology, Patterns of Care, and Mortality for Patients With Acute Respiratory Distress Syndrome in Intensive Care Units in 50 Countries. JAMA. 2016 Feb 23;315(8):788-800. doi: 10.1001/jama.2016.0291. PubMed 26903337 ↗

Individual participant data

Plan to share: No

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Oct 2027, 10 months later.

Of 228 non-industry observational studies under Respiratory Distress Syndrome, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 47. This study's planned 10 months is below that.

Counting every sponsor, half of 234 studies reached it within 24 months; a quarter within 12 and three quarters within 49.

Start moved once since we started tracking on Sep 25, 2026: Oct 2026 → Nov 2026, on Nov 17, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2026
First posted
Oct 5, 2026
StartEst.
Nov 20, 2026was Oct 2026
Primary completionEst.
Oct 10, 2027
CompletionEst.
Dec 31, 2027
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Oct 10, 2026→Nov 20, 2026
Nov 17, 2026
Secondary outcomes
2 time frame changed
What changed in the outcomes
  • Time frameCumulative Fluid BalanceFrom Day 0 to Day 7 → From Day 1 to Day 7
  • Time frameChange in Oxygenation Index (PaO2/FiO2 Ratio)From Day 0 to Day 7 → From Day 1 to Day 7
Oct 13, 2026
Registered
First appeared on the registry
Oct 5, 2026
Show all 3 updates
  1. Nov 17, 2026
    Start date Oct 10, 2026→Nov 20, 2026
    + 1 other change: verification date
  2. Oct 13, 2026
    Secondary outcomes 2 time frame changed
    What changed in the outcomes
    • Time frameCumulative Fluid BalanceFrom Day 0 to Day 7 → From Day 1 to Day 7
    • Time frameChange in Oxygenation Index (PaO2/FiO2 Ratio)From Day 0 to Day 7 → From Day 1 to Day 7
    + 1 other change: description
  3. Oct 5, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07857928
Lead sponsor
The Second Affiliated Hospital of Hainan Medical University
Responsible party
Sponsor
First posted
Oct 5, 2026
Start date
Nov 20, 2026 (estimated)
Primary completion
Oct 10, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Nov 17, 2026

Study contacts

Fengyun Wang, MD/PhD
Contact
dr-w@qq.com
8619389918115

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion